Business Wire

Panda Biotech Announces Commercial Operations Have Begun at Its Flagship Panda Hemp Gin

Share

Panda Biotech™ announced today that commercial operations have officially begun at the Panda Hemp Gin, their landmark industrial hemp processing facility in Wichita Falls, Texas. The 500,000-square-foot building situated on 97 acres is the first of its kind and the largest in the Western Hemisphere, with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. It is a zero-waste process, utilizing every part of the industrial hemp stalk, and operates solely on 100 percent renewable energy, making it a paragon of sustainability in the industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240403426324/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Panda Hemp Gin is a 500,000-square-foot building situated on 97 acres with the capacity to process 10 metric tons of industrial hemp into textile-grade fiber, hurd, short-fiber/hurd mix, and nutrient-rich micronized hurd per hour. (Photo: Business Wire)

The Panda Hemp Gin is fully operational, and production will continue to ramp up in the coming months. In February, the complex commissioning process of Panda's 600-yard-long processing line and three miles of overhead pneumatic duct lines, including each piece of equipment for decortication, refining, blending, mechanical cottonization, hurd bagging and storage, and baling, was successfully completed.

"Panda Biotech's state-of-the-art industrial hemp processing facility is a monumental achievement and a game-changer for both agriculture and industry,” said Dixie Carter, president of Panda Biotech. “As research and development in this area continue to advance, industrial hemp fiber and cellulose will help transform numerous industries with sustainable goals and challenges. Panda’s industrial hemp will play a pivotal role in satisfying significant global market demand for renewable processes and products.”

Industrial hemp is considered one of the most versatile raw materials available with an unmatched variety of potential uses. The Panda Hemp Gin will focus on providing five main product lines from hemp, including mechanically cottonized fiber, decorticated fiber, hurd (cellulose), short-fiber/hurd mix, and nutrient-rich micronized hemp dust. The innumerous applications for each product vary broadly from consumer and industrial textiles, non-wovens, paper products, bioplastics, biofuel, animal bedding, fiberglass substitute, construction materials such as hempcrete, mulch, insulation, and more.

With a commitment to traceability and processing only U.S.-grown hemp straw, as well as providing an astounding pay-to-grow program, Panda’s partnership with the American farming community is at the heart of the operation. Industrial hemp provides a multitude of benefits for producers, as it is scientifically proven to minimize CO2 emissions, absorbing more per acre than any forest or commercial crop. Additionally, hemp requires significantly less water than most major crops, provides outstanding soil remediation, and requires minimal fertilizers, pesticides, and herbicides. Panda is actively contracting with producers for its pay-to-grow program for this harvest and with farmers who may have straw or fiber from previous harvests or the 2024 growing season. Interested producers can reach out to Panda through the website at pandabiotech.com.

"The massive scale of the campus, allowing more than 22,000 pounds of baled hemp straw for processing per hour, is what makes this industrial hemp processing facility unique,” said Scott Evans, chief operating officer of Panda Biotech. “Our straw is sourced directly from our farming partners in Texas and surrounding states, and, through our decortication process, it is transformed into packaged products, ready for retail or downstream manufacturing applications, within minutes. Panda's processing equipment and infrastructure is truly best-in-class."

For more information, please visit www.pandabiotech.com and follow us at @pandabiotech on Facebook, Instagram, X, and LinkedIn.

ABOUT PANDA BIOTECH

Based in Dallas, Texas, privately-held Panda Biotech, LLC is a first-mover in the emerging U.S. industrial hemp fiber and hurd industry that is 100 percent American-owned, grown, and processed. Panda Biotech’s executive leadership has extensive experience developing, financing, constructing, and operating large-scale infrastructure facilities in clean energy. They have developed 22 projects representing approximately $12 billion in invested capital. Panda Biotech’s first project, the Panda Hemp Gin™, is in partnership with Aka-Ag, LLC, a wholly-owned subsidiary of the Southern Ute Indian Tribe Growth Fund. The facility is located in Wichita Falls, Texas. It is the largest industrial hemp processing facility of its kind in the Western Hemisphere.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Beth Gebhard
SVP, Marketing and Public Relations
beth.gebhard@pandabiotech.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Shines a Light on Inequalities and Unmet Needs in Care as Part of Its Commitment to People With Cardiovascular Disease31.8.2024 18:00:00 EEST | Press release

Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced its reinforced commitment to addressing key unmet needs and barriers in cardiovascular (CV) care, by shining a light on inequalities in treatment and outcomes experienced by various patient groups. The announcement follows the presentation of data from sub-analyses of the SANTORINI observational study and ETNA-AF (Edoxaban Treatment in routiNe clinical prActice in patients with nonvalvular Atrial Fibrillation) study programme, at the European Society of Cardiology (ESC) Congress 2024. Gender inequalities in CV disease treatment and LDL-C goal attainment Raised low-density lipoprotein cholesterol (LDL-C) is a key modifiable contributor to risk of cardiovascular major events. It has been shown that for every 1 mmol/L reduction in LDL-C, there is a 22% reduction in major cardiovascular events after 1 year.7,8 Female patients in Europe who are at high or very high CV risk were undertreated and less achieved guideline-recomm

Suzano completes purchase of 15% stake in Lenzing AG31.8.2024 01:40:00 EEST | Press release

Suzano, the world's largest pulp producer, today announces the completion of its acquisition of a 15% stake in Lenzing AG, the Vienna-listed leading global supplier of sustainable premium cellulosic fibres for the textile and non-wovens industry, from B&C Group. As announced in June this year, the transaction value is EUR 230 million (or EUR 39.70 per share). The agreement was subject to regulatory approval, which was granted without restrictions. The long-term partnership between Suzano and B&C Group establishes that Suzano has the right to hold two seats on Lenzing’s Board and the option to acquire an additional 15% stake from B&C Group until the end of 2028. Following the sale of the 15% stake, B&C Group now holds 37.25% of Lenzing’s share capital. Lenzing is a leading global supplier of premium wood-based cellulosic fibers (lyocell, modal, and viscose) for the production of clothing, home textiles, hygiene products, and non-woven materials. Beto Abreu, CEO of Suzano, said: “Lenzing

Ant International Collaborates with Brazilian Partners to Drive Financial Inclusion with Innovative Credit Tech Solutions30.8.2024 21:46:00 EEST | Press release

Ant International, a digital payment and financial technology leader, today announced its strategic initiative to provide AI-driven credit technology solutions designed to empower local partners and advance financial inclusions in Brazil. As a major milestone, Ant International has formed a strategic partnership with Dock, a leader in payments and banking technology in Latin America. This collaboration aims to enhance the credit management capability and infrastructure efficiency for Dock’s clients, which include financial institutions, retailers, fintech start-ups, etc. The shared vision is to make credit services more inclusive for market segments that are currently insufficiently served, such as micro, small and medium-sized enterprises (MSMEs). In the initial phase of the collaboration, Ant International’s AI-driven credit tech solutions, including an automated and intelligent risk management engine, will be explored for integration into Dock One platform. This initiative aims to s

Wipro Appoints Srikumar Rao as Global Head of Its Engineering Edge Business Line30.8.2024 17:20:00 EEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Srikumar Rao as Global Head of its Engineering Edge Business Line, effective from October 5, 2024. Srikumar succeeds Harmeet Chauhan, who is stepping down to pursue opportunities outside the organization. Srikumar will report to Srini Pallia. Srikumar has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Chief Operating Officer (COO) of Wipro Engineering Edge (WEE) and Global Practice Head of Embedded Systems. His work has spanned several markets, selling and delivering specialized Engineering, Research, and Development (ER&D) services to Software & Internet, Semiconductor, Automotive, Manufacturing, and Communications clients. In his new role, Srikumar will continue to scale and strengthen Wipro’s engineering prowess. He will also be responsible for defining the vision

Alnylam Presents Detailed Results from the Positive HELIOS-B Phase 3 Study of Vutrisiran▼ in Patients with ATTR Amyloidosis with Cardiomyopathy at the European Society of Cardiology Congress30.8.2024 13:00:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced detailed results from the HELIOS-B Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM). The data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2024, taking place August 30-September 2 in London, United Kingdom. Results from the HELIOS-B study were also simultaneously published in TheNew England Journal of Medicine. As previously reported, the HELIOS-B study met all 10 of its primary and secondary endpoints, across both the overall and monotherapy populations, with statistical significance. Enrolled patients were predominantly New York Heart Association (NYHA) Class I or II with wild-type disease and had been diagnosed by non-invasive methods, with substantial concurrent treatment with available standard of care treatments such as tafamidis and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye